Nocturnal/Diurnal Intraocular Pressure-Lowering Effect of Netarsudil Ophthalmic Solution

Conditions

• Ocular Hypertension
• Open Angle Glaucoma

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• Netarsudil ophthalmic solution 0.02% — DRUG
  Once daily in both eyes (OU) in the evening (PM) for 7 days
• Netarsudil Ophthalmic Solution Vehicle — OTHER
  Once daily in both eyes (OU) in the evening (PM) for 7 days

Study Details

To evaluate effect of Netarsudil Ophthalmic Solution 0.02% on Nocturnal and Diurnal Intraocular Pressure.

Key Dates

Start date

Jul 31, 2016

Status verified

Oct 2016

Primary completion

Sep 30, 2016

Completion

Sep 30, 2016

Study Design

Enrollment

12 participants (actual)

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Arms

• Experimental: Netarsudil Ophthalmic Solution 0.02%
  1 drop in each eye (OU) daily
• Placebo Comparator: Netarsudil Ophthalmic Solution Vehicle
  1 drop in each eye (OU) daily

Primary Outcome Measure

Change in Intraocular Pressure (IOP) Over Nocturnal Time Period [ Time Frame: Assessed over 24 hours at 9 pm, midnight, 3 am and 6 am on days 1/2 and 8/9 ]

Locations (1)

Find similar trials in Bedminster, NJ

Related Studies

• Study of the CycloPen Micro-Interventional System and Long-Term Clinical Outcomes
  Enrolling By Invitation · Iantrek, Inc. · Newport Beach, California
• Bioequivalence Study With Clinical Endpoint Comparing Bimatoprost Ophthalmic Solution 0.01% and LUMIGAN® in the Treatment of Chronic Open-Angle Glaucoma or Ocular Hypertension in Both Eyes.
  PHASE3 · Recruiting · Amneal Pharmaceuticals, LLC · Newport Beach, California
• Nanodropper Use in Primary Open-Angle Glaucoma Patients: A Non-Inferiority Trial
  Recruiting · 59th Medical Wing · Lackland Air Force Base, Texas
• A Randomized, Double-blind, Parallel-group, Two-arm, Multiple Dose, Multicenter, Bioequivalence Study With Clinical Endpoint in the Treatment of Subjects With Chronic Open-angle Glaucoma or Ocular Hypertension in Both Eyes
  PHASE1 · Recruiting · Amneal Pharmaceuticals, LLC · Bakersfield, California